Daily Stock Analysis, CNCE, Concert Pharmaceuticals Inc, priceseries

Concert Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
14.57
Close
14.32
High
14.57
Low
14.06
Previous Close
14.60
Daily Price Gain
-0.28
YTD High
15.32
YTD High Date
Feb 19, 2019
YTD Low
12.07
YTD Low Date
Jan 2, 2019
YTD Price Change
0.75
YTD Gain
5.53%
52 Week High
26.15
52 Week High Date
Mar 9, 2018
52 Week Low
10.80
52 Week Low Date
Nov 14, 2018
52 Week Price Change
-6.88
52 Week Gain
-32.45%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 22. 2016
9.54
Jan 9. 2017
10.21
10 Trading Days
7.03%
Link
LONG
Mar 2. 2017
9.60
Mar 30. 2017
16.60
20 Trading Days
72.94%
Link
LONG
Nov 10. 2017
17.53
Dec 21. 2017
25.94
28 Trading Days
48.00%
Link
LONG
Dec 31. 2018
12.55
Jan 14. 2019
14.02
9 Trading Days
11.70%
Link
Company Information
Stock Symbol
CNCE
Exchange
NasdaqGM
Company URL
http://www.concertpharma.com
Company Phone
781-860-0045
CEO
Roger D. Tung
Headquarters
Massachusetts
Business Address
99 HAYDEN AVENUE, SUITE 500, LEXINGTON, MA 02421
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001367920
About

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs for renal disease, CNS disorders, inflammation and hematologic disorders. It also creates novel medicines that address commercially important needs by applying its deuterated chemical entity platform to compounds with well-characterized pharmacological activity. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Description

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. The company's clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis. It product candidates that have completed Phase 1 clinical trials comprise CTP-730 for use in the treatment of inflammation or cancer; JZP-386 for use in the treatment of excessive daytime sleepiness and cataplexy; and CTP-543 for use in the treatment of alopecia areata. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.